Erzotabart是一种人源化IgG1κ型单克隆抗体，特异性靶向CD38（ADP-核糖环化酶1/cADPR水解酶1），通过介导抗体依赖性细胞毒性（ADCC）及补体依赖性细胞毒性（CDC）等机制发挥抗肿瘤活性。

/

粉末-25~-15℃保存，有效期3年；溶于溶剂，-85~-65℃保存，有效期2年。

[1] Hiemstra IH, Santegoets KCM, Janmaat ML, De Goeij BECG, Ten Hagen W, van Dooremalen S, Boross P, van den Brakel J, Bosgra S, Andringa G, van Kessel-Welmers B, Verzijl D, Hibbert RG, Frerichs KA, Mutis T, van de Donk NWCJ, Ahmadi T, Satijn D, Sasser AK, Breij ECW. Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity. EBioMedicine. 2023 Jul;93:104663. doi: 10.1016/j.ebiom.2023.104663. Epub 2023 Jun 26. PMID: 37379657; PMCID: PMC10320249.